Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer

Nuclear Medicine Communications

Volumn 33, Issue 7, 2012, Pages 775-779

  Soussan, Michaël ^a   Nataf, Valérie ^a   Kerrou, Khaldoun ^a   Grahek, Dany ^a   Pascal, Odile ^a   Talbot, Jean Noël ^a   Montravers, Françoise ^a  

^a HÔPITAL TENON   (France)

Author keywords

18F FDOPA PET CT; early acquisition; medullary thyroid cancer

Indexed keywords

6 FLUORODOPA F 18;

ADULT; AGED; ARTICLE; BODY MASS; BONE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LIVER; LYMPH NODE; LYMPH NODE METASTASIS; MALE; MEDULLARY THYROID CANCER; RECURRENT CANCER; RETROSPECTIVE STUDY; THYROID CANCER; WHOLE BODY CT; WHOLE BODY PET;

ADULT; AGED; CARCINOMA, MEDULLARY; DIHYDROXYPHENYLALANINE; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TIME FACTORS;

EID: 84862158643     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283543304     Document Type: Article

References (11)

1. Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: Relation to tumor differentiation. J Nucl Med 2008; 49:524-531.
2. Beheshti M, Pocher S, Vali R, Waldenberger P, Broinger G, Nader M, et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: Comparison with 18F-FDG PET-CT. Eur Radiol 2009; 19:1425-1434.
3. Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro- DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2007; 34:1604-1609.
4. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001; 28:64-71.
5. Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 2010; 20:527-533.
6. Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, et al. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging. Eur J Surg Oncol 2010; 36:414-421.
7. Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med 2006; 47:1455-1462.
8. Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008; 26:1489-1495.
9. Neels OC, Koopmans KP, Jager PL, Vercauteren L, van Waarde A, Doorduin J, et al. Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4- dihydroxy- L-phenylalanine accumulation in neuroendocrine tumor cells. Cancer Res 2008; 68:7183-7190.
10. Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: Basic aspects and emerging clinical applications. J Nucl Med 2008; 49:573-586.
11. Pestourie C, Theze B, Kuhnast B, Le Helleix S, Gombert K, Dolle F, et al. PET imaging of medullary thyroid carcinoma in MEN2A transgenic mice using 6-[(18)F]F-L-DOPA. Eur J Nucl Med Mol Imaging 2010; 37:58-66.